首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
【24h】

A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.

机译:因子Xa的合成抑制剂DX-9065a在大鼠体内可降低血管平滑肌细胞的增殖。

获取原文
获取原文并翻译 | 示例
           

摘要

The effect of factor Xa inactivation on the proliferation of vascular smooth muscle cells in vivo was investigated in an experimental restenosis model in rats by using the direct factor Xa inhibitor DX-9065a. In the left common carotid artery, an injury of the vascular endothelium was produced by four external vessel clamps for 60 minutes. After 14 days, 3H-labeled methyl thymidine and 5-bromo-2'-deoxyuridine, respectively, were injected intraperitoneally. After 24 hours, both the left (damaged) and right (nondamaged) carotid arteries were removed, and the incorporation of 3H-methyl thymidine/microg protein was determined. For morphological analysis, the cells were labeled with hematoxylin as well as 5-bromo-2'-deoxyuridine. Stained vascular smooth muscle cell nuclei were counted, and the proliferation index (percentage of 5-bromo-2'-deoxyuridine-positive nuclei to total nuclei stained with hematoxylin) was determined. An external damage of the carotid artery induced proliferation of vascular smooth muscle cells and formation of a neointima within 2 weeks after vessel injury. As compared with control animals, single subcutaneous injection of DX-9065a (2.5, 5, and 10 mg/kg) given 30 minutes before vessel injury significantly reduced the incorporation of 3H-methyl thymidine/microg protein and the total cell number, as well as the proliferation index. The antiproliferative action of DX-9065a was not dose dependent in the range from 2.5 to 10 mg/kg s.c. A combination of bolus injection (5 mg/kg s.c.) with continuous administration (5 mg/kg/d s.c. for 7 and 14 days, respectively) did not increase the antiproliferative effect of DX-9065a. The results indicate a role of factor Xa in the complex pathogenesis of restenosis and the usefulness of a highly effective and selective inhibitor of factor Xa to inhibit proliferative processes.
机译:使用直接因子Xa抑制剂DX-9065a在大鼠的再狭窄实验模型中研究了因子Xa失活对体内血管平滑肌细胞增殖的影响。在左颈总动脉中,四个外部血管夹钳持续60分钟,对血管内皮造成了损伤。 14天后,腹膜内注射3H标记的甲基胸苷和5-溴-2'-脱氧尿苷。 24小时后,去除了左侧(受损)和右侧(未受损)的颈动脉,并确定了3H-甲基胸苷/微克蛋白的掺入。为了进行形态分析,将细胞用苏木精以及5-溴-2'-脱氧尿苷标记。对染色的血管平滑肌细胞核进行计数,并测定增殖指数(5-溴-2'-脱氧尿苷阳性核与苏木精染色的总核的百分比)。颈动脉的外部损伤在血管损伤后2周内诱导了血管平滑肌细胞的增殖和新内膜的形成。与对照组动物相比,在血管损伤前30分钟单次皮下注射DX-9065a(2.5、5和10 mg / kg)可显着减少3H-甲基胸苷/微克蛋白的掺入以及总细胞数作为扩散指数。 DX-9065a的抗增殖作用在2.5至10 mg / kg s.c的范围内与剂量无关。推注(5 mg / kg s.c.)与连续给药(分别为5 mg / kg / d s.c. 7天和14天)的组合不能增加DX-9065a的抗增殖作用。结果表明,因子Xa在再狭窄的复杂发病机理中的作用以及因子Xa的高效选择性抑制剂抑制增殖过程的有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号